Cancer Drug Price Caps Leave Nearly 1 in 4 Packs Unchanged

An analysis of data released by the National Pharmaceutical Pricing Authority shows that recent government measures to cap trade margins on non-scheduled anti-cancer drugs have lowered maximum retail prices for the majority of listed medicine packs. While 484 out of 643 packs saw decreases, nearly one in four packs remained unchanged.

The initiative, announced to address excessive trade margins and improve treatment affordability, resulted in steep price cuts exceeding 90% for a small number of entries. However, analysts noted that 53 out of 56 entries priced above one lakh rupees saw no reductions at all.

Experts have raised concerns that the policy primarily impacts generics and biosimilars, leaving high-value originator brands untouched. This dynamic could allow hospitals to continue stocking expensive options while keeping lower-priced alternatives out of reach, according to legal and health advisors.

Observers also caution that reductions in maximum retail prices do not automatically equate to direct savings for every patient. Actual relief depends on previous purchase prices, hospital compliance, and the specific medications required.